Cardiogenesis’ Phoenix TMR plus biologic
This article was originally published in The Gray Sheet
Executive Summary
Phoenix gains CE mark approval, enabling a "controlled" European launch, the firm announces Oct. 10. The advanced combination delivery system administers Cardiogenesis' transmyocardial revascularization laser treatment in conjunction with biologic therapy, such as autologous bone marrow stems cells, for advanced coronary artery disease not treatable with bypass surgery. Initial clinical data, along with ongoing research, will help determine "the appropriate regulatory, reimbursement and commercial strategies in the U.S.," the firm states. The combination Ho:YAG laser energy/biologic delivery system also can be used with drugs, according to Cardiogenesis...
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.